#United States #Eurofins Viracor #Lenexa #Pneumococcal #Immunocompromised

Eurofins Viracor Launches Advanced Pneumococcal Antibody Assays

In a significant advancement for immunocompromised patient care, Eurofins Viracor has unveiled a new multiplexed bead-based assay specifically designed to detect IgG responses to available pneumococcal vaccines. This launch marks an important milestone as it extends coverage to a wider array of serotypes, enabling clinicians to better monitor vaccine-induced immunity for patients at higher risk.

What’s New?

The newly released pneumococcal antibody assays include testing for vaccines like the recently approved Pneumococcal 21-valent Conjugate Vaccine (PCV21). Eurofins Viracor now offers tests for multiple serotypes: PCV15, PCV20, PPSV23, and PCV21, alongside a comprehensive assay covering 32 unique serotypes of Streptococcus pneumoniae. This suite of assays empowers clinicians with a powerful tool to evaluate the immune response to these critical vaccines.

The highlights of this launch include coverage of newly recognized serotypes, such as 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B, which were previously not included in standard vaccines. By broadening the range of detectable serotypes, this initiative aims to enhance the accuracy of immune response monitoring for immunocompromised patients, ensuring that management of their health is both personalized and precise.

Unmatched Accuracy and Precision

Eurofins has committed to delivering assays that comply with international standards set forth by the World Health Organization (WHO). The validated assays are proven to achieve an impressive accuracy and precision rate of 100% at the clinically relevant IgG cutoff of 1.3 µg/mL. Notably, research indicates that immunocompetent individuals show elevated IgG responses compared to their immunocompromised counterparts, highlighting the crucial need for specialized monitoring.

Addressing a Critical Need

The introduction of these pneumococcal antibody assays responds to a vital gap in diagnostics, leveraging advanced immunology technology to facilitate fast, sensitive, and specific detection of pneumococcal antibody levels. Eurofins Viracor underscores its dedication to innovation in immunology diagnostics through this critical advancement.

For healthcare professionals and patients alike, these new assays hold the promise of improved health outcomes. Having access to broader serotype testing and accurate monitoring is essential for guiding patient care and ensuring better health management for those who are immunocompromised.

About Eurofins Viracor

Eurofins Viracor brings over four decades of diagnostic expertise in infectious diseases, allergies, and immunology, focusing particularly on the needs of immunocompromised patients. The company is committed to providing actionable results that truly connect laboratories with the patients they support. As a subsidiary of Eurofins Scientific, Eurofins Viracor stands at the forefront of bio-analytical testing and genomic services on a global scale.

For more detailed information on the new pneumococcal antibody assays, interested parties can visit Eurofins Viracor's website or reach out to their Client Services at (800) 305-5198.